ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Sep 16, 2017
Valuentum's September Edition of Its Best Ideas Newsletter
The link to download the September edition of the Best Ideas Newsletter can be found in this article.
Sep 14, 2017
Apple: Innovation Versus Improvements
Image Source: Valuentum. Apple’s 2017 iPhone event took place September 12, and it was one of the most highly anticipated of such events. Let’s take a look at what improvements are being made and how they might impact our thesis on the tech giant.
Sep 14, 2017
Upadacitinib Posts Impressive Data for AbbVie
Image Source: AbbVie. In the pharmaceutical realm, the productivity of the clinical pipeline is essential to replace the loss of revenue due to an expiration of the patent life of a product. AbbVie is facing the monumental task of having to diversify away from the top-selling pharmaceutical product in the world with little in the way of assurances the transition will be a success. We are pleased with the recent data release on Upadacitinib as we view the molecule as AbbVie’s top R&D product.
Sep 13, 2017
Earnings Snapshot: Cracker Barrel’s Hidden 5%+ Dividend Yield
Cracker Barrel is holding its share-price uptrend nicely. The company is one of our favorite restaurants thanks in part to its differentiated niche and country store concept. Special dividend payouts make it a hidden income gem, in our view.
Sep 12, 2017
Target, Kroger Launch Counterattack on Amazon-Whole Foods; Industry Earnings to Shrink
Image Source: Valuentum. The pricing war has begun, but it may take years before we see the final effects. Only the strongest may come out ahead, and only those already focusing on giving customers the very best value proposition at the lowest prices may retain share.
Sep 11, 2017
Canakinumab Posts Some Impressive Data For Novartis
Image Source: Novartis. We remain impressed with the depth of the clinical pipeline that is currently being brought out to market by the Dividend Growth Newsletter portfolio idea Novartis. We closely follow the data delivered from clinical trials to gauge the potential for the pipeline; in the case of Novartis, we feel the strength of the emerging pipeline bodes very well for continued dividend growth over the next few years. In this piece, we will detail the clinical results for Canakinumab, as we feel the molecule will nicely complement Novartis’ burgeoning cardiovascular unit.
Sep 9, 2017
Dividend Increases/Decreases for the Week Ending September 8
Let's take a look at companies raising/lowering their dividends this week.
Sep 9, 2017
Fair Value Estimates of Stocks In Our Coverage Universe
In this article, use the download to view the fair value estimates of companies in our coverage universe.
Sep 9, 2017
Rank Our Coverage Universe By Valuentum Buying Index Rating
Use the download in this article to rank our coverage universe by each firm's respective Valuentum Buying Index rating.
Sep 8, 2017
The Wisdom of Oaktree's Howard Marks
Image Source: emmolos. The latest memo from Oaktree's Howard Marks here should be read and then read again. The section on passive investing is an absolute treasure. "Passive investing is done in vehicles that make no judgments about the soundness of companies and the fairness of prices.  More than $1 billion is flowing daily to “passive managers” (there’s an oxymoron for you) who buy regardless of price.  I’ve always viewed index funds as “freeloaders” who make use of the consensus decisions of active investors for free.  How comfortable can investors be these days, now that fewer and fewer active decisions are being made?" -- Howard Marks, Oaktree Capital


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.